← Back to patent-cliff list
MT-1002(Shaanxi Micot Technology)
Tier C — Watch / tradeMT-1002(Shaanxi Micot Technology)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GP IIb/IIIa
Indications (approved)：ST段抬高型心肌梗死, Unstable angina, 非ST段抬高型心肌梗死, Acute coronary syndrome, Ischaemic stroke, Stroke, 血液凝固障碍, Thrombosis
Regional status
US
Discontinued
2020-12-02
EU
-
China
Phase II
2024-02-27
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of MT-1002(Shaanxi Micot Technology)?
Approved indications include: ST段抬高型心肌梗死, Unstable angina, 非ST段抬高型心肌梗死, Acute coronary syndrome, Ischaemic stroke, Stroke, 血液凝固障碍, Thrombosis.
When does the MT-1002(Shaanxi Micot Technology) patent expire?
No public expiry year is available for MT-1002(Shaanxi Micot Technology) yet; this page updates once verified.
How do I get a quote for MT-1002(Shaanxi Micot Technology) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06